Cancer Detection Method
AssigneeSienna Cancer Diagnostics Inc.
InventorsMatthew Hoskin, Minesh Lalla, Shannon Turnbull
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of determining whether a subject has cancer. More particularly, the present disclosure relates to a method of determining whether a subject has cancer when a pathological assessment of cell morphology is negative for the cancer. More particularly, the present disclosure relates to a method of determining whether a morphologically normal cell is malignant. Identification of malignant cells, when a pathological assessment of cell morphology is negative for cancer, is based upon detecting the binding of an anti-telomerase antibody to clinically relevant cells.
Claims22
A method of identifying malignant cells in a sample obtained from a subject when a pathological assessment of cell morphology performed on the sample is negative for cancer, the method comprising, contacting cells from the sample with an anti-telomerase antibody and performing a pathological assessment of the cells to detect binding of the antibody to clinically relevant cells, wherein binding of the antibody to clinically relevant cells indicates the presence of malignant cells.
A method of determining whether a subject has cancer
- (a) when a pathological assessment of cell morphology performed on a sample obtained from the subject is negative for cancer, the method comprising:
- i) contacting a sample obtained from the subject with an anti-telomerase antibody;
- ii) performing a pathological assessment of the sample to detect binding of the antibody to clinically relevant cells in the sample;
- wherein binding of the antibody to one or more clinically relevant cells in the sample indicates that the subject has cancer, or
- (b) the method comprising:
- i) performing a pathological assessment of cell morphology on a sample obtained from the subject to determine the morphology of one or more clinically relevant cells in the sample;
- ii) contacting a sample from the subject with an anti-telomerase antibody and performing a pathological assessment of the sample to detect binding of the antibody to clinically relevant cells in the sample;
- wherein when the assessment of cell morphology is negative for cancer, binding of the antibody to one or more clinically relevant cells indicates that the subject has cancer.
(canceled)
(canceled)
-12. (canceled)
(canceled)
(canceled)
-26. (canceled)
A method comprising:
- prescribing treatment of a subject for cancer,
- wherein a pathological assessment of cell morphology performed on a sample from the subject is negative for cancer, and
- wherein an anti-telomerase antibody binds to one or more clinically relevant cells in sample from the subject.
Dependencies are inferred from the claim text.